The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR
Open accessAbstract
BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases (Ki, <2 nmol/L). It is currently in phase I development for the treatment of a variety of human cancers. BMS-754807 effectively inhibits the growth of a broad range of human tumor types in vitro, including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, gastric), and hematopoietic (multiple myeloma and leukemia) tumor cell lines (IC50, 5–365 nmol/L); the compound caused apoptosis in a human rhabdomyosarcoma cell line, Rh41, as shown by an accumulation of the sub-G1 fraction, as well as by an increase in poly ADP ribose polymerase and Caspase 3 cleavage. BMS-754807 is active in vivo in multiple (epithelial, mesenchymal, and hematopoietic) xenograft tumor models with tumor growth inhibition ranging from 53% to 115% and at a minimum effective dose of as low as 6.25 mg/kg dosed orally daily. Combination studies with BMS-754807 have been done on multiple human tumor cell types and showed in vitro synergies (combination index, <1.0) when combined with cytotoxic, hormonal, and targeted agents. The combination of cetuximab and BMS-754807 in vivo, at multiple dose levels, resulted in improved clinical outcome over single agent treatment. These data show that BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family–targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents. [Mol Cancer Ther 2009;8(12):3341–9]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Insulin-like growth factors and neoplasia
Pollak, M. N., Schernhammer, E. S., & Hankinson, S. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1387 · Cited by 1,463
Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., et al. (2004) · Nature Medicine · doi:10.1038/nm1003 · Cited by 965
Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., & Vigneri, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3278 · Cited by 902
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Garofalo, R. S., Orena, S. J., Rafidi, K., Torchia, A. J., Stock, J. L., Hildebrandt, A. L., Coskran, T., Black, S. C., Brees, D. J., Wicks, J. R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16885 · Cited by 726
The IGF‐1 receptor in cancer biology
Baserga, R., Peruzzi, F., & Reiss, K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11487 · Cited by 642
The insulin-like growth factor I receptor: a key to tumor growth?
Baserga, R. (1995) · PubMed · Cited by 552
Cited by
Interventions to slow aging in humans: are we ready?
Longo, V. D., Antebi, A., Bartke, A., Barzilai, N., Brown‐Borg, H. M., Caruso, C., Curiel, T. J., Cabo, R., Franceschi, C., Gems, D., et al. (2015) · Aging Cell · doi:10.1111/acel.12338 · Cited by 592
“treat several types of cancer (Warshamana-Greene et al., 2005; Carboni et al., 2009); however, none have been approved for clinical use.”
Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma
Zhang, X. H.-F., Jin, X., Malladi, S., Zou, Y., Wen, Y. H., Brogi, E., Smid, M., Foekens, J. A., & Massagué, J. (2013) · Cell · doi:10.1016/j.cell.2013.07.036 · Cited by 425
The proliferating role of insulin and insulin-like growth factors in cancer
Gallagher, E. J., & LeRoith, D. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.007 · Cited by 380
Okamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00183 · Cited by 328
Insulin/IGF-1 Drives PERIOD Synthesis to Entrain Circadian Rhythms with Feeding Time
Crosby, P., Hamnett, R., Putker, M., Hoyle, N. P., Reed, M., Karam, C. J., Maywood, E. S., Stangherlin, A., Chesham, J. E., Hayter, E. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.017 · Cited by 309
Metadata
- Authors
- Carboni, J. M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., Hillerman, S., Cao, C., Cantor, G. H., Dell-John, J., Chen, C., Discenza, L., Menard, K., Li, A., Trainor, G., Vyas, D., Kramer, R., Attar, R. M., & Gottardis, M. M.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2009-12-01
- Volume
- 8
- Issue
- 12
- Pages
- 3341-3349
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2106321700
- Cited by
- 280
- References
- 37
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-0499
- The paper
- Carboni, J. M., Wittman, M., Yang, Z., Lee, F., Greer, A., Hurlburt, W., Hillerman, S., Cao, C., Cantor, G. H., Dell-John, J., Chen, C., Discenza, L., Menard, K., Li, A., Trainor, G., Vyas, D., Kramer, R., Attar, R. M., & Gottardis, M. M. (2009). BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-0499
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.